Results from the Global Phase 3 Trial (IB1001-303) Evaluating Levacetylleucine in Children and Adults with Ataxia-Telangiectasia (LS1.001)

Key Points

• To evaluate the efficacy and safety of levacetylleucine in individuals diagnosed with Ataxia-Telangiectasia.
• Conducted as a pivotal Phase 3 trial
• Included both children and adults
• Analyzed efficacy and safety results
• Efficacy results demonstrate significant improvement in symptoms associated with Ataxia-Telangiectasia.
• Safety profile remains consistent with previous findings, with manageable side effects.